If you are like me you are sitting around with your fingers crossed waiting for the cure.  So I thought I would share with you excerpts from an article I received from a business publication.  The cure is not here yet, but apparently they’re working on it.  (I am leaving the first paragraph in even though I don’t understand it, but it might be significant to men on hormone therapy.)

———————————————————————————————————–

There are no Less than 280 Therapeutics Targeting Prostate Cancer Today

DUBLIN, Ireland–(BUSINESS WIRE)–Research and Markets ) has announced the addition of “Prostate Cancer: Drug Pipeline Update 2008” to their offering.
Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. The prostate cancer market is reaching maturity, and major players` sales have been eroded by the launch of various LHRH agonist depot formulations. Safety concerns with AstraZeneca`s Casodex (bicalutamide) have also seen a significant proportion of physicians switching to alternatives. Establishing the optimal timing of antihormonal therapy will provide the key to market growth.

There are today no less than 280 therapeutics targeting prostate cancer, from early preclinical to marketed drugs. Prostate Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to more than 160 different targets. These targets are further categorized on the CD-ROM by 51 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Prostate Cancer Drug Pipeline Update is organized. . .